HAL Id: inserm-00515302
https://www.hal.inserm.fr/inserm-00515302
Submitted on 1 Jul 2011
HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages.
Thérèse Hèrvée Mayi, Christian Duhem, Corinne Copin, Mohamed Amine Bouhlel, Elena Rigamonti, François Pattou, Bart Staels, Giulia
Chinetti-Gbaguidi
To cite this version:
Thérèse Hèrvée Mayi, Christian Duhem, Corinne Copin, Mohamed Amine Bouhlel, Elena Riga- monti, et al.. Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages.: Visfatin induction by PPARgamma in human macrophages. FEBS Journal, Wiley, 2010, 277 (16), pp.3308-20. �10.1111/j.1742-4658.2010.07729.x�. �inserm-00515302�
Figure 1
AcLDL
1 2 3 4
GW1929 RSG Control
Visfatin / cyclophilin mRNA
A
** **
******
Visfatin / cyclophilin mRNA
1 2 3 4 6 5
**
***
***
C
1 2 3 4
Visfatin / cyclophilin mRNA
B
0
*
*
*
*
* 5
D
Visfatin / cyclophilin mRNA
0.5 1 1.5 2 2.5
*
ATM
1 2
3
E
Visfatin / cyclophilin mRNA *
1 2 3
F
Visfatin / cyclophilin mRNA 4
RSG Control
***
***
* Control
GW1929
§
RSG Control
RSG Control
GW1929 GW1929
Control GW1929
1 2
3 RSG
Control
CD36 / cyclophilin mRNA
G
1 2 3 4 5 6 7
***
***
*
***
***
*
RSG Control
FABP4 / cyclophilin mRNA
H
Figure 2
1 2 3
m CD 3 6 / cy clop h ilin m RN A RSG
Control GW1929
*
*
m V isf a tin / cy clop h ilin m RN A
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
RSG Control GW1929
CD 3 6 / cy clop h ilin m RN A
0.5 1 1.5 2 2.5 3
V isf a tin / cy clop h ilin m RN A
0.2 0.4 0.6 0.8 1 1.2 1.4
A B
C D
Control ***
GW1929
Control
GW1929
Figure 3
B
RLU /b-gal x 1000
pSG5
**
(DR1-Visfatin PPRE)
6b-gal x 1000
2 4 6 8 10 12 14
pSG5-PPARg Control
GW1929
RLU /b-gal x 1000
**
(DR1-consensus PPRE)
6RLU /b-gal x 1000
*
10
20 30 40 50 60
70 Control GW1929
pSG5 pSG5-PPARg
A
RXRa+ PPARg
DR1-Visfatin-PPRE wt
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2
1 3
DR1-consensus PPRE
§§
§§§
Figure 4
A B
V isf a tin / cy clop h ilin m RN A
1 2 3 4 5 6 7
V isf a tin / cy clop h ilin m RN A
GW1929 Control
*
*
***
***
**
**
ns
0.5 1 1.5 2 2.5
§ §§
§§
Control
**
**
*
*
*
GW1929
V isf a tin se cr e tio n (ng /m L ) Visfatin
b-actin
Figure 5
0.4 0.8 1.2 1.6
V isf a tin /
b-a ctin
A B
0.2 0.6 1.0
1.4 * ***
0.5
1
1.5
2
2.5
Figure 6
In trace llu la r NAD+ co n ce n trat io n (%)
20 40 60 80 100 120 140
scrambled siRNA visfatin
A
20 40 60 80 100 120
140 B C
vehicle FK866
80 90 100 110 120 130 140
RSG Control GW1929
AdGFP AdPPARg
§§
§
* *
*
* *
* * * * *
§
§
* *
*
In trace llu la r NAD+ co n ce n trat io n (%) In trace llu la r NAD+ co n ce n trat io n (%)
GW1929 Control
GW1929 Control
